2-Mercaptoethanol/DMSO Workflow: Mouse Liver and Ovarian Cancer Proteomics Data

Arisa Suto's dataset compares proteomics workflows for cysteine alkylation, published on figshare in May 2026. It contains quantitative proteomics data from mouse liver samples processed with either a novel 2-mercaptoethanol/DMSO treatment or a conventional iodoacetamide method, and from ovarian clear cell carcinoma samples. The data supports the finding that the 2-ME/DMSO workflow increased cysteine-modified peptide counts by 1.6- to 1.9-fold and improved quantitative reproducibility.

Use Cases

• Benchmarking quantitative reproducibility of proteomics workflows based on reported coefficients of variation (CV).
• Comparing protein sequence coverage between alkylation methods based on the reported 77% improvement.
• Analyzing cisplatin-induced protein alterations in ovarian cancer based on the application mentioned in the description.
• Evaluating the impact of cysteine alkylation strategies on peptide identification based on the reported 1.6-1.9 fold increase.

Strengths

• Includes specific performance metrics: 1.6- to 1.9-fold increase in cysteine-modified peptides.
• Reports quantitative reproducibility improvements: peptide CV ≤ 20% increased from 61.4% to 86.1%.
• Demonstrates improved protein sequence coverage for 77% of identified proteins.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale modeling.
• Data size is 44.6 MB, indicating a relatively small-scale proteomics study.

Provenance

Source

Arisa Suto via figshare.

Collection Method

Mouse liver proteomes processed with 2-ME/DMSO or IAA treatments, followed by LC-MS/MS analysis.

Freshness

Last updated 2026-05-08 06:47:02; freshness should be verified.